NICE Guidance - November 2022
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of November 2022. This month there is one technology appraisal that impacts upon primary care.
The Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis technology appraisal has been terminated. NICE is unable to make a recommendation because the manufacturer withdrew its evidence submission. The decision will be reviewed if the company decides to make a submission.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « SMC Update - November 2022 | Antiviral Medicines Authorised for Influenza Season 2022/23 » |
Leave a Comment